BOYDE HARRISON: Open Payments
NPI 1619908571 · HALEYVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$836 in 38 payments from 17 companies in 2025. Trend: 2023 $6,770 · 2024 $1,008 · 2025 $836
Food & beverage: $836
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $163 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $125 |
| Indivior Inc. | 4 | $69 |
| Corcept Therapeutics | 3 | $59 |
| Novartis Pharmaceuticals Corporation | 2 | $58 |
| ABBVIE INC. | 3 | $51 |
| Braeburn Inc. | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Gilead Sciences, Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $37 |
Products named: FARXIGA, XIFAXAN, SUBLOCADE, Korlym, LEQVIO, VRAYLAR, BRIXADI, REXULTI.
Industry payments across AL — which companies pay providers there.
